Here Are the Four Verdicts.
Four companies. Four Firewall runs. Four different versions of the same question: is the filing confirming what the price already assumes?
Here is what the evidence showed this week.
Crocs (CROX) · Watch
The foam clog is not the bet. HEYDUDE is. Ten times operating earnings is compelling if the channel correction story holds. The gross margin behavior during HEYDUDE’s revenue decline is the single most diagnostic number in the next filing. Above 40 percent means pricing power is intact and the problem is distribution. Below that means the brand is discounting to defend volume it no longer commands at full price. Those two outcomes look identical in revenue terms. The unit economics reveal which one you are actually looking at.
AbbVie (ABBV) · Clear for Deeper Research
The only positive verdict this week. Skyrizi and Rinvoq growing 49 and 50 percent year over year with $4.9 billion in combined quarterly revenue. The revenue math of the Humira transition is working. The filing evidence is directionally supportive. The open question is whether the margin math is keeping pace. Humira carried gross margins above 85 percent historically. The immunology segment gross margin in the Q1 10-Q is the number that confirms or questions the economics of the transition at this scale.
Sherwin-Williams (SHW) · Watch
Twenty-nine times earnings on a recovery that has not fully confirmed. The Paint Stores Group operating leverage thesis only works if volume returns, not just revenue. If Sherwin-Williams is raising prices on a declining contractor base the earnings story the multiple requires does not exist yet. More jobs at higher prices is the operating leverage story. Higher prices on fewer jobs is a different story entirely. The same-store sales volume decomposition in the Q1 segment discussion answers which one is playing out.
GE Vernova (GEV) · Watch
One hundred thirty-five times earnings is not an absurd valuation. It is a specific prediction that earnings will multiply from here as the $44 billion gas turbine backlog converts. The Wind segment guiding to a $400 million EBITDA loss in 2026 while demand is at an all-time high is the concrete proof that backlog size and backlog profitability are not the same thing. Strong demand does not fix contracts signed at prices that do not cover current costs. The Power segment margin direction and Wind EBIT trajectory in Q2 are the two numbers that tell you whether the conversion story is earning its valuation.
The Stock Story Firewall runs any company in two minutes. The Evidence Intelligence Tool tests the assumption against the actual filing.
Run any company: firewall.readthelongview.com